Furthermore, Hanna et al. [45] reported that HNSCC-patients with a high CD8+ lymphocyte rate and PD-1 expression were correlated with improved response rates with anti-PD-1/PD-L1 agents. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.